论文部分内容阅读
目的:对预混胰岛素血糖控制效果不理想的2型糖尿病患者实施利拉鲁肽与甘精胰岛素联合治疗,并对其临床疗效加以探究。方法:选取该院2014年3月至2015年3月所接收的预混胰岛素血糖控制不佳2型糖尿病患者86例作为观察对象,按就诊单双数顺序法分为甲组与乙组,前者予以甘精胰岛素+阿卡波糖,后者予以甘精胰岛素+利拉鲁肽。比较2组患者的临床疗效。结果:乙组患者治疗后的各血糖值(FPG、2hPG、HbA1c)对于本组治疗前及甲组治疗后,差异明显(P<0.05);乙组患者的低血糖发生次数少于甲组(P<0.05)。结论:对预混胰岛素血糖控制不佳2型糖尿病者实施甘精胰岛素与利拉鲁肽联合治疗,可有效控制患者的血糖,且降低低血糖的发生次数,值得推行。
OBJECTIVE: To conduct a combination therapy of liraglutide and insulin glargine in patients with type 2 diabetes with poorly controlled premixed insulin glycemic control and investigate its clinical efficacy. Methods: Totally 86 patients with poorly controlled type 2 diabetes mellitus with preblended insulin received from March 2014 to March 2015 in our hospital were selected as observation subjects. Patients were divided into group A and group B according to the single and double order of attendance. Glargine + Acarbose, the latter to insulin glargine + liraglutide. The clinical effects of two groups were compared. Results: The blood glucose (FPG, 2hPG, HbA1c) after treatment in group B was significantly different from that before treatment and after treatment in group A (P <0.05); the number of hypoglycemia in group B was less than that in group A P <0.05). Conclusion: The combination therapy of insulin glargine and liraglutide in patients with type 2 diabetes with poorly controlled blood glucose in premixed insulin can effectively control the blood glucose and reduce the incidence of hypoglycemia, which is worth promoting.